Skip to main content
OpenTrials
Completed

NCT Number: NCT00372372

The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Tuen Mun Hospital

Hong Kong, China

About this study

We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or equivalent for at least 6 weeks.
  • Age>=18 years and <75 years.

Exclusion criteria

  • Pregnant or lactating women.
  • Uncorrected hypocalcemia.
  • History of esophageal stricture.
  • Previous intolerance or hypersenstivity to biphosphonates.

Treatment and study plan

risedronate

Drug

Primary outcomes

  1. bone mineral density

Secondary outcomes

  1. Adverse events, new vertebral fractures

Sponsors and collaborators

Lead sponsor

Tuen Mun Hospital

Other Gov

Registry information

Important dates

Study start
2004
Study completion
2007
First posted
Sep 6, 2006
Registry last updated
Sep 28, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.